Testing a medication to prevent cancer return after lung surgery

This trial is testing a medication called osimertinib in patients who have had early-stage lung cancer surgically removed and have a specific EGFR gene mutation. The goal is to see if taking this medication every day for three years after surgery can keep the cancer from coming back. This is called adjuvant therapy—treatment given after surgery to reduce the risk of recurrence.

Early-stage lung cancer can sometimes return even after successful surgery, especially in patients with certain genetic markers. Researchers want to know if this medication, which targets the specific EGFR mutation, can lower the risk of recurrence when given as a preventive treatment after surgery.